Healthcare Services

Dyspnea Market Expansion Outlook Through 2030 With Revenue Growth Insights

May 28, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Will Be The Estimated Market Size Of The Dyspnea Market By 2030?

The dyspnea market has experienced robust expansion in recent years. It is projected to expand from $6.73 billion in 2025 to $7.22 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.4%. This historical growth is largely due to factors such as chronic respiratory disease prevalence, hospital emergency admissions, smoking-related disorders, the aging population, and the cardiopulmonary disease burden.

The dyspnea market size anticipates substantial expansion over the upcoming years. It is projected to reach $9.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period is due to factors such as the demand for portable oxygen systems, remote respiratory monitoring, personalized dyspnea management, the expansion of homecare services, and digital symptom tracking. Key trends anticipated during this period encompass the increasing utilization of oxygen therapy devices, a rise in the adoption of home-based respiratory care, an intensifying focus on symptom management therapies, the incorporation of breathing and relaxation techniques, and enhanced diagnostic assessment of respiratory disorders.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21178&type=smp

What Major Growth Factors Are Impacting The Dyspnea Market?

The growing incidence of respiratory ailments is projected to boost the dyspnea market’s expansion moving forward. Respiratory diseases are conditions affecting the lungs and respiratory system, leading to impaired airflow and reduced oxygen exchange. The rise in these conditions stems from factors such as air pollution, smoking, environmental toxins, climate change, and increased susceptibility in aging populations. The dyspnea market is supported by this trend because dyspnea acts as a crucial indicator of compromised lung function, aiding clinicians in diagnosing respiratory issues, formulating treatment plans, and tracking disease progression. For instance, in June 2024, the Australian Institute of Health and Welfare, an Australia-based government agency, reported that in 2023, COPD contributed 3.6% to the total disease burden and constituted 50% of the total burden from respiratory diseases. In 2022, COPD was the leading cause of 7,691 deaths, with a mortality rate of 29.6 per 100,000 people, accounting for 4.0% of all deaths. Thus, the increasing prevalence of respiratory diseases is stimulating the growth of the dyspnea market.

Which Segment Divisions Form The Structure Of The Dyspnea Market?

The dyspnea market covered in this report is segmented –

1) By Treatment Type: Supplemental Oxygen Therapy, Relaxation Therapy

2) By Drug Class: Antianxiety, Antibiotics, Anticholinergic Agents, Corticosteroids, Other Drug Classes

3) By Route Of Administration: Oral, Inhalation, Other Route Of Administrations

4) By End User: Hospitals, Homecare, Specialty Clinics, Ambulatory Services, Other End Users

Subsegments:

1) By Supplemental Oxygen Therapy: Continuous Flow Oxygen Therapy, Pulse Dose Oxygen Therapy, Oxygen Concentrators, Portable Oxygen Cylinders

2) By Relaxation Therapy: Breathing Exercises, Meditation and Mindfulness, Progressive Muscle Relaxation, Biofeedback Therapy

What Trends Are Driving Changes In The Dyspnea Market?

Leading firms within the dyspnea market are concentrating their efforts on creating novel drug treatments, including phosphodiesterase (PDE) inhibitors, aiming to enhance the effectiveness of therapy, alleviate respiratory issues, and offer superior comfort to individuals experiencing persistent breathing problems. A phosphodiesterase (PDE) inhibitor functions as a drug that obstructs PDE enzymes, thereby elevating intracellular levels of cyclic AMP or cyclic GMP, which in turn stimulates bronchodilation, diminishes inflammation, and boosts general respiratory performance. As an illustration, in May 2024, Verona Pharma Plc, a biopharmaceutical entity based in the UK, declared its preparations for the anticipated U.S. introduction of ensifentrine, a pioneering dual PDE3/4 inhibitor designed for chronic obstructive pulmonary disease (COPD), with its launch projected for Q3 2024, contingent on FDA approval. Ensifentrine, administered through nebulization, has demonstrated substantial decreases in COPD exacerbation frequencies and notable improvements in dyspnea during Phase III trials. Verona also successfully obtained $650 million in funding to facilitate its commercial introduction and continued advancement, encompassing a planned Phase II fixed-dose combination study involving glycopyrrolate for ongoing COPD treatment.

Who Are The Prominent Players Across The Dyspnea Market?

Major companies operating in the dyspnea market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca, Novartis AG, GlaxoSmithKline, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Amneal Pharmaceuticals LLC, Lupin Ltd, Inogen Inc, Fisher & Paykel Healthcare, ResMed Inc, Koninklijke Philips N.V, Masimo Corporation, Breas Medical, PARI Medical Holding GmbH, BMC Medical, Hamilton Medical, Nihon Kohden Corporation, Cipla Inc

Access The Complete Dyspnea Market Report:

https://www.thebusinessresearchcompany.com/report/dyspnea-global-market-report

Which Geographic Region Represents The Largest Dyspnea Market Share?

North America was the largest region in the dyspnea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dyspnea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Dyspnea Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21178&type=smp

Browse Through More Reports Similar to the Global Dyspnea Market 2026, By The Business Research Company

Dysphagia Supplement Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/dysphagia-supplement-global-market-report

Sleep Apnea Devices Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sleep-apnea-devices-global-market-report

Airway Stent Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/airway-stent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795